SI1007686T1 - Vakcina proti tuberkulozi - Google Patents

Vakcina proti tuberkulozi

Info

Publication number
SI1007686T1
SI1007686T1 SI9830871T SI9830871T SI1007686T1 SI 1007686 T1 SI1007686 T1 SI 1007686T1 SI 9830871 T SI9830871 T SI 9830871T SI 9830871 T SI9830871 T SI 9830871T SI 1007686 T1 SI1007686 T1 SI 1007686T1
Authority
SI
Slovenia
Prior art keywords
nucleic acid
acid molecules
present
tuberculosis vaccine
novel recombinant
Prior art date
Application number
SI9830871T
Other languages
English (en)
Inventor
Stefan H E Kaufmann
Juergen Hess
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of SI1007686T1 publication Critical patent/SI1007686T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI9830871T 1997-08-22 1998-08-12 Vakcina proti tuberkulozi SI1007686T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97114614A EP0902086A1 (en) 1997-08-22 1997-08-22 Tuberculosis vaccine
PCT/EP1998/005109 WO1999010496A1 (en) 1997-08-22 1998-08-12 Tuberculosis vaccine
EP98947427A EP1007686B1 (en) 1997-08-22 1998-08-12 Tuberculosis vaccine

Publications (1)

Publication Number Publication Date
SI1007686T1 true SI1007686T1 (sl) 2007-04-30

Family

ID=8227261

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830871T SI1007686T1 (sl) 1997-08-22 1998-08-12 Vakcina proti tuberkulozi

Country Status (13)

Country Link
US (1) US6673353B1 (sl)
EP (2) EP0902086A1 (sl)
JP (1) JP4255209B2 (sl)
AT (1) ATE347599T1 (sl)
AU (1) AU9435098A (sl)
CA (1) CA2301879C (sl)
CY (1) CY1106350T1 (sl)
DE (1) DE69836588T2 (sl)
DK (1) DK1007686T3 (sl)
ES (1) ES2274580T3 (sl)
PT (1) PT1007686E (sl)
SI (1) SI1007686T1 (sl)
WO (1) WO1999010496A1 (sl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7635479B2 (en) 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
ID29858A (id) 1998-11-04 2001-10-18 Isis Innovation Uji diagnostik tuberkulosis
GB0006693D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Vaccine
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
ATE552843T1 (de) * 2003-02-06 2012-04-15 Aduro Biotech Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen
CA2523084C (en) 2003-04-23 2012-09-04 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Tuberculosis vaccine with improved efficacy
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
DK1827504T3 (da) 2004-12-01 2011-08-29 Aeras Global Tb Vaccine Foundation Rekombinante BCG-stammer med forøget evne til at undslippe fra endosomet
DK2977456T3 (en) 2006-08-15 2018-01-22 Univ Pennsylvania Compositions comprising HMW-MAA and fragments thereof for the treatment of cancer
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2403935B1 (en) 2009-03-04 2017-05-10 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
ES2784451T3 (es) * 2010-09-20 2020-09-25 Vakzine Projekt Man Gmbh Mycobacterium recombinante como vacuna para uso en seres humanos
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
WO2012085099A1 (en) * 2010-12-21 2012-06-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Determination of the efficacy of an anti-mycobacterial vaccination
CN108434448A (zh) * 2010-12-21 2018-08-24 马克斯·普朗克科学促进学会 作为疫苗的重组分枝杆菌
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
BR102012003790A2 (pt) 2012-02-17 2014-04-22 Fundacao Butantan Cepa de mycobacterium recombinante, composição imunogênica e uso
JP2015511602A (ja) 2012-03-12 2015-04-20 アドバクシス, インコーポレイテッド リステリアワクチン処理後のサプレッサー細胞機能抑制
AU2013243922A1 (en) * 2012-04-02 2014-10-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine

Also Published As

Publication number Publication date
CA2301879C (en) 2014-02-04
DE69836588D1 (de) 2007-01-18
ES2274580T3 (es) 2007-05-16
JP4255209B2 (ja) 2009-04-15
AU9435098A (en) 1999-03-16
ATE347599T1 (de) 2006-12-15
DK1007686T3 (da) 2007-04-10
WO1999010496A1 (en) 1999-03-04
CA2301879A1 (en) 1999-03-04
US6673353B1 (en) 2004-01-06
DE69836588T2 (de) 2007-04-05
PT1007686E (pt) 2007-03-30
CY1106350T1 (el) 2011-10-12
EP1007686B1 (en) 2006-12-06
EP1007686A1 (en) 2000-06-14
JP2001514000A (ja) 2001-09-11
EP0902086A1 (en) 1999-03-17

Similar Documents

Publication Publication Date Title
SI1007686T1 (sl) Vakcina proti tuberkulozi
HK1091217A1 (en) Tuberculosis vaccine with improved efficacy
DK1025211T3 (da) Hyaluronansyntasegen og anvendelser deraf
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
HK1013847A1 (en) Gdf-1 and uog-1 proteins
WO2001053455A3 (en) Novel nucleic acids and polypeptides
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
EP1132479A4 (en) PROTEIN EXPRESSION VECTOR AND USE THEREOF
AU1013701A (en) Modified gp100 and uses thereof
DK251890D0 (da) Polypeptid og dets anvendelse samt ekspressionssystem til dets eksprimering
DE69637856D1 (en) Interleukin-19.
CA2121364A1 (en) Vaccines for actinobacillus pleuropneumoniae
GB9922361D0 (en) Generating an immune response to an antigen
MX9708426A (es) Polipeptido hk2 de variante estable.
IL125797A0 (en) Parapoxviruses which contain foreign dna their preparation and their use in vaccines
FI20070041A (fi) Parannettu rokote Flavivirusinfektioiden vastaiseen immuunisointiin
IL90334A0 (en) Genetic transformation of b.thuringiensis,vectors used therefor,host cells transformed by the vectors and use of said cells as insecticides
ZA985393B (en) Clostridium perfringens vaccine
DK0919621T3 (da) Human TAK1 og DNA der koder derfor
CA2148369A1 (en) Actinobacillus pleuropneumoniae outer membrane lipoprotein a and uses thereof
ATE315646T1 (de) Leukocyten-aktivierender faktor
WO2002010379A3 (en) Modified cea and uses thereof
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium
AU6518298A (en) Novel dna vector and vaccines containing novel recombinant dna vectors as the active ingredient